Biopharmaceutical company
Appears in 1 story · Last updated Oct 31, 2026
Developer of Lucamzi; first US approval October 2026
After four years and two FDA rejections, Xbrane Biopharma has US approval for its copy of Lucentis, one of the world's best-selling eye drugs. Xbrane announced the approval on October 27, two days before the FDA's October 29 review deadline.
Updated Oct 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
